No approved hantavirus vaccine exists for general use in the US or most Western countries as of mid-2026, with only limited inactivated options like South Korea’s Hantavax available elsewhere. Leading DNA vaccine candidates targeting Hantaan, Puumala, and Andes viruses have advanced through Phase 1 and early Phase 2 trials showing immunogenicity, yet none have entered Phase 3 efficacy studies required for licensure. Moderna’s mRNA candidate remains preclinical, and the May 2026 cruise ship outbreak—while prompting renewed research attention and prioritization—has not altered the multi-year timelines typical for regulatory approval. Trader consensus at 94.5% for no vaccine by year-end reflects these confirmed development stages and historical precedents for slow progress on low-incidence pathogens, though an unexpected emergency authorization or accelerated trial could theoretically shift outcomes.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
6% chance
$130,985 Vol.
$130,985 Vol.
Dec 30, 2026
6% chance
$130,985 Vol.
$130,985 Vol.
Dec 30, 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No approved hantavirus vaccine exists for general use in the US or most Western countries as of mid-2026, with only limited inactivated options like South Korea’s Hantavax available elsewhere. Leading DNA vaccine candidates targeting Hantaan, Puumala, and Andes viruses have advanced through Phase 1 and early Phase 2 trials showing immunogenicity, yet none have entered Phase 3 efficacy studies required for licensure. Moderna’s mRNA candidate remains preclinical, and the May 2026 cruise ship outbreak—while prompting renewed research attention and prioritization—has not altered the multi-year timelines typical for regulatory approval. Trader consensus at 94.5% for no vaccine by year-end reflects these confirmed development stages and historical precedents for slow progress on low-incidence pathogens, though an unexpected emergency authorization or accelerated trial could theoretically shift outcomes.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Market Opened: May 4, 2026, 10:39 AM ET
Volume
$130,985End Date
Dec 31, 2026Market Opened
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No approved hantavirus vaccine exists for general use in the US or most Western countries as of mid-2026, with only limited inactivated options like South Korea’s Hantavax available elsewhere. Leading DNA vaccine candidates targeting Hantaan, Puumala, and Andes viruses have advanced through Phase 1 and early Phase 2 trials showing immunogenicity, yet none have entered Phase 3 efficacy studies required for licensure. Moderna’s mRNA candidate remains preclinical, and the May 2026 cruise ship outbreak—while prompting renewed research attention and prioritization—has not altered the multi-year timelines typical for regulatory approval. Trader consensus at 94.5% for no vaccine by year-end reflects these confirmed development stages and historical precedents for slow progress on low-incidence pathogens, though an unexpected emergency authorization or accelerated trial could theoretically shift outcomes.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Volume
$130,985End Date
Dec 31, 2026Market Opened
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...No approved hantavirus vaccine exists for general use in the US or most Western countries as of mid-2026, with only limited inactivated options like South Korea’s Hantavax available elsewhere. Leading DNA vaccine candidates targeting Hantaan, Puumala, and Andes viruses have advanced through Phase 1 and early Phase 2 trials showing immunogenicity, yet none have entered Phase 3 efficacy studies required for licensure. Moderna’s mRNA candidate remains preclinical, and the May 2026 cruise ship outbreak—while prompting renewed research attention and prioritization—has not altered the multi-year timelines typical for regulatory approval. Trader consensus at 94.5% for no vaccine by year-end reflects these confirmed development stages and historical precedents for slow progress on low-incidence pathogens, though an unexpected emergency authorization or accelerated trial could theoretically shift outcomes.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions